Yale School of Medicine, Department of Neurology, PO Box 208018, New Haven, CT, 06520, USA; VA Connecticut Healthcare System, Headache Center of Excellence, Neurology Service, MS 127, 950 Campbell Avenue, West Haven, CT, 06516, USA.
Neuropharmacology. 2022 Sep 1;215:109166. doi: 10.1016/j.neuropharm.2022.109166. Epub 2022 Jun 16.
The effects of psychedelic drugs in headache and chronic pain disorders have been reported for several decades, and now controlled studies are emerging. The existing evidence supports a lasting therapeutic benefit after limited dosing, a unique feature of the drug class that distinguishes it from conventional treatment. This commentary summarizes these reports of preventive effects of psychedelic drugs in headache and chronic pain disorders. The recently published controlled trial of psilocybin in migraine is reviewed, including its limitations. Several neurobiological targets of psychedelics that are related to headache and chronic pain are highlighted, though a clear separation of acute and lasting effects is key in uncovering the unique clinical effects of this drug class. Considerable investigation is required before the effects, safety, and mechanism of action of psychedelics in headache and chronic pain disorders can be known.
几十年来，已有报道称迷幻药物对头痛和慢性疼痛障碍有治疗作用，且目前正在开展对照研究。现有证据支持在有限剂量下药物能产生持久的治疗益处，这是该药物类别的独特特征，使其有别于传统治疗方法。本文总结了迷幻药物在头痛和慢性疼痛障碍中的预防作用的相关报告。本文还对近期发表的关于迷幻蘑菇治疗偏头痛的对照试验进行了综述，包括其局限性。文中强调了迷幻药物与头痛和慢性疼痛相关的几个神经生物学靶点，但要揭示该药物类别的独特临床效果，关键是要区分急性和持久作用。在了解迷幻药物在头痛和慢性疼痛障碍中的作用、安全性和作用机制之前，还需要进行大量研究。
